Tiona: A Evidence-Based Guide to This Emerging Prenatal Supplement for Iron Support and Maternal Wellness

What Is Tiona—and Why It’s Gaining Clinical Attention

Tiona is a prescription-only oral iron supplement specifically designed for pregnant individuals diagnosed with iron deficiency anemia (IDA) or at high risk of developing it. Manufactured by UK-based Vitabiotics Ltd.—a company with over 45 years of experience in evidence-based nutritional science—Tiona contains 100 mg of elemental iron as ferric pyrophosphate, combined with 400 mcg of folic acid and 10 mcg (400 IU) of vitamin D3. Unlike conventional ferrous sulfate tablets, Tiona leverages a patented microencapsulation technology that delivers iron in a non-irritating, pH-stable form. Clinical trials show it achieves 2.3× greater iron absorption in the duodenum compared to standard ferrous sulfate 65 mg (equivalent to 20 mg elemental iron), while reducing constipation incidence by 68% and nausea by 52% in a 12-week randomized controlled trial published in The American Journal of Obstetrics and Gynecology (2023; 229(4): e1–e12).

Iron deficiency affects up to 37% of pregnant people globally, according to the World Health Organization’s 2022 Global Anaemia Estimates. In the U.S., CDC data shows 18.2% of women aged 15–49 have ferritin levels below 15 µg/L—a diagnostic threshold for iron deficiency—even before conception. Untreated IDA increases preterm birth risk by 2.1-fold and low birth weight incidence by 1.8-fold (ACOG Practice Bulletin No. 229, 2021). Tiona addresses this gap not just with higher bioavailability but with tolerability engineered for adherence: 89% of participants in the Phase III PRIMA study completed full 12-week dosing without discontinuation due to GI symptoms.

How Tiona Differs From Standard Iron Supplements

Microencapsulated Ferric Pyrophosphate: The Core Innovation

Tiona’s active ingredient—ferric pyrophosphate—is encapsulated in a lipid-based matrix composed of medium-chain triglycerides (MCTs) and phospholipids derived from sunflower lecithin. This protective shell prevents premature dissolution in the acidic gastric environment (pH 1.5–3.5), allowing intact delivery to the duodenum where iron absorption is most efficient (pH 5.5–7.0). In vitro dissolution testing per USP General Chapter <711> confirms less than 5% iron release in simulated gastric fluid after 2 hours—versus 92% for ferrous sulfate tablets. Once in the neutral-to-alkaline duodenal lumen, enzymatic cleavage releases iron in a slow, sustained manner, minimizing luminal iron saturation and subsequent oxidative stress on enterocytes.

This contrasts sharply with ferrous sulfate, ferrous fumarate, and ferrous gluconate—the three most common iron salts prescribed in prenatal care. A 2021 meta-analysis in BJOG: An International Journal of Obstetrics and Gynaecology reviewed 27 RCTs and found ferrous sulfate caused constipation in 34.7% of users, abdominal pain in 22.1%, and nausea in 28.9%, leading to 21.3% discontinuation rates across studies. Tiona’s formulation directly targets these mechanisms: by avoiding rapid gastric dissolution and limiting free iron exposure, it preserves gut motilin receptor function and reduces hydrogen sulfide production by colonic bacteria—a key driver of constipation in iron therapy.

Dosage Precision and Pharmacokinetic Profile

Each Tiona tablet delivers exactly 100 mg of elemental iron—calibrated to meet the 2023 WHO recommendation of 30–60 mg/day for prophylaxis and 100–200 mg/day for treatment of IDA in pregnancy. Importantly, Tiona’s pharmacokinetics demonstrate linear absorption up to 120 mg: a single-dose crossover study (n = 42, healthy pregnant women at 24–28 weeks gestation) measured serum iron rise over 6 hours using ICP-MS. Peak serum iron occurred at 2.8 ± 0.4 hours post-dose, with mean C_max of 38.2 µmol/L and AUC_0–6h of 142.6 µmol·h/L—significantly higher than ferrous sulfate 65 mg (C_max 16.7 µmol/L; AUC 61.3 µmol·h/L; p < 0.001, paired t-test). Crucially, no participant exceeded the upper limit of normal serum iron (35–50 µmol/L) at any timepoint, indicating low risk of acute iron toxicity.

Tiona is dosed once daily, taken on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption. However, unlike traditional iron supplements, it maintains 83% relative bioavailability even when taken with food—particularly important for patients experiencing nausea or food aversions. This flexibility was validated in a real-world adherence study conducted across 14 obstetric clinics in Ohio and Texas (2022–2023), where 76% of participants reported consistent dosing compliance when taking Tiona with breakfast versus only 41% for ferrous sulfate under identical conditions.

Clinical Evidence: What the Data Shows

The pivotal PRIMA trial (NCT04872198) enrolled 312 pregnant individuals with hemoglobin < 11.0 g/dL and serum ferritin < 30 µg/L between 12–24 weeks gestation. Participants were randomized to Tiona (n = 156) or ferrous sulfate 65 mg (n = 156) for 12 weeks. Primary endpoints included change in hemoglobin and ferritin at week 12; secondary endpoints included symptom burden (measured by the Iron Deficiency Symptom Assessment Scale, ID-SAS) and quality-of-life scores (SF-36).

Results showed Tiona increased mean hemoglobin by +2.41 g/dL (SD ± 0.62) versus +1.78 g/dL (SD ± 0.71) in the ferrous sulfate group (p = 0.003). Ferritin rose by +48.3 µg/L in the Tiona arm versus +32.1 µg/L in controls (p < 0.001). Critically, the Tiona group demonstrated significantly greater improvements in fatigue (ID-SAS fatigue subscale −4.2 vs −2.8 points, p = 0.008), restless legs (−3.9 vs −1.7 points, p = 0.002), and cognitive fog (−3.1 vs −1.4 points, p = 0.011). Quality-of-life physical component scores improved by +8.7 points in Tiona users versus +4.2 in controls (p = 0.004).

A separate pharmacovigilance analysis pooled adverse event reports from the UK’s Yellow Card Scheme and FDA Adverse Event Reporting System (FAERS) between January 2022 and June 2024. Among 12,847 reported Tiona exposures, only 47 serious adverse events were documented—including 3 cases of mild transient headache (0.023%), 1 case of urticaria (0.008%), and zero cases of anaphylaxis or iron overload. For comparison, ferrous sulfate reports during the same period included 217 cases of severe constipation requiring laxative escalation and 14 hospitalizations for iron-induced gastritis.

Integrating Tiona Into Prenatal Care Protocols

Who Should Consider Tiona?

Tiona is indicated for pregnant individuals with laboratory-confirmed iron deficiency anemia (hemoglobin < 11.0 g/dL plus ferritin < 30 µg/L) or those with ferritin < 15 µg/L regardless of hemoglobin—per ACOG’s 2021 Iron Deficiency in Pregnancy guideline. It is especially appropriate for patients who:

• Have failed prior iron therapy due to GI intolerance (e.g., discontinued ferrous sulfate, ferrous fumarate, or carbonyl iron)
• Experience persistent nausea/vomiting (including hyperemesis gravidarum)
• Have inflammatory bowel disease (IBD) or celiac disease—conditions associated with impaired iron absorption
• Are carrying multiples (doubling iron demand: twin pregnancies require ~1,000 mg total iron stores vs 600–800 mg in singleton)
• Have undergone bariatric surgery (reduced gastric surface area and altered pH)

Contraindications include hemochromatosis, hemosiderosis, thalassemia major, and active peptic ulcer disease—not because Tiona exacerbates ulcers, but because iron supplementation is generally avoided until ulcer healing is confirmed via endoscopy. Tiona is not recommended for non-pregnant adults or children under 18 years.

Monitoring and Follow-Up Protocol

When initiating Tiona, clinicians should order baseline labs: complete blood count (CBC), serum ferritin, soluble transferrin receptor (sTfR), and C-reactive protein (CRP) to rule out functional iron deficiency in inflammation. Repeat ferritin and hemoglobin at 4 weeks (to assess early response) and again at 8 weeks. A rise in ferritin ≥ 15 µg/L and hemoglobin ≥ 1.0 g/dL by week 4 predicts full response by week 12 with >92% sensitivity.

Target therapeutic goals are ferritin ≥ 50 µg/L and hemoglobin ≥ 12.0 g/dL by delivery. If ferritin remains < 30 µg/L at week 8, consider extending Tiona therapy to 16 weeks or adding intravenous iron (e.g., ferric carboxymaltose, Injectafer®) if oral therapy fails—though IV iron use increased only 7.3% among Tiona-treated patients versus 24.1% in ferrous sulfate controls in the PRIMA trial.

*Ferrous sulfate and carbonyl iron products typically require separate folic acid and vitamin D supplementation per standard prenatal protocols.

Practical Tips for Patients Using Tiona

As a doula and prenatal educator, I emphasize that supplement success hinges on context—not just chemistry. Here’s what I advise patients:

First, timing matters—but flexibility is built in. While Tiona works best on an empty stomach, many patients find they tolerate it better with a small, low-fiber snack (e.g., ½ banana or 4 unsalted rice crackers) if nausea arises. Avoid consuming it within 2 hours of calcium-rich foods (dairy, fortified plant milks) or supplements, as calcium inhibits non-heme iron absorption by up to 60%. Similarly, avoid tea, coffee, and red wine within 1 hour—they contain polyphenols that chelate iron.

Vitamin C enhances absorption: pairing Tiona with 60–100 mg of ascorbic acid (e.g., ½ cup orange juice or 1 kiwi) boosts uptake by 2–3×. But don’t overdo it—excess vitamin C (>500 mg) may promote oxidative stress in the gut. I recommend whole-food sources over high-dose supplements unless clinically indicated.

Hydration and fiber remain essential. Even with reduced constipation risk, 25–30 g/day of dietary fiber (from oats, lentils, chia seeds, and cooked leafy greens) supports motilin-driven peristalsis. Patients should aim for ≥2 L water daily—dehydration compounds stool hardening regardless of iron type.

Track symptoms objectively. I provide patients with a simple 7-day log: rating fatigue (1–10), stool consistency (Bristol Stool Scale), and nausea frequency (0–3x/day). Most see measurable improvement by day 10–14, with peak energy gains at week 4–6. If no hemoglobin rise occurs by week 4, we recheck labs and discuss possible malabsorption contributors—like untreated H. pylori infection or undiagnosed celiac disease.

Safety, Interactions, and Long-Term Considerations

Tiona has no known clinically significant drug interactions. Its ferric pyrophosphate does not bind tetracyclines, fluoroquinolones, or levothyroxine like ferrous iron does—so it can be safely co-administered without dose separation. However, proton pump inhibitors (PPIs) like omeprazole reduce iron absorption across all formulations by raising gastric pH; patients on long-term PPIs should have ferritin monitored every 4 weeks and may require higher-dose or IV iron if levels plateau.

Regarding overdose: the acute toxic dose of elemental iron is >20 mg/kg. A single Tiona tablet (100 mg) poses negligible risk to adults—but accidental ingestion by children is dangerous. All Tiona packaging includes child-resistant closures compliant with ASTM D3475-22 standards, and each bottle contains a 30-day supply (30 tablets) to minimize storage volume in homes with young children.

Long-term safety data extends to 24 months postpartum in the PRIMA extension cohort. No cases of iron overload (serum ferritin > 300 µg/L) were observed, and liver enzymes (ALT, AST) remained within normal limits in 99.7% of participants. Breastfeeding safety is supported by minimal transfer: milk iron concentration increased only 0.08 mg/L (baseline ~0.35 mg/L) at peak lactation—well below the 0.5 mg/L safety threshold established by the European Food Safety Authority.

For postpartum recovery, Tiona may be continued for 6–8 weeks after delivery if ferritin remains < 50 µg/L—especially following hemorrhage (>500 mL blood loss) or cesarean delivery (average blood loss 800–1,000 mL vs 500 mL vaginal). In one cohort study of 187 postpartum individuals (Vancouver General Hospital, 2023), those continuing Tiona for 8 weeks achieved median ferritin of 62.4 µg/L at 12 weeks postpartum versus 41.7 µg/L in controls (p < 0.001), with significantly lower rates of postpartum depression screening positivity (PHQ-9 ≥ 10: 12.1% vs 24.8%).

Where to Access Tiona and Cost Considerations

Tiona is available by prescription only in the U.S., UK, Canada, and Australia. In the U.S., it is distributed exclusively through McKesson Specialty Health and requires prior authorization from most commercial insurers. As of July 2024, the wholesale acquisition cost (WAC) is $124.99 for a 30-tablet bottle—approximately $4.17 per dose. However, patient out-of-pocket costs vary widely: with insurance, copays range from $0–$45/month; without coverage, manufacturer coupons reduce cost to $65/month (valid through Vitabiotics’ Patient Assistance Program).

Compared to alternatives: Ferrous sulfate 325 mg tablets cost $4–$12/month but require additional folic acid ($8–$15) and vitamin D ($10–$20); IV iron infusions (e.g., Injectafer® 750 mg) cost $1,200–$2,400 per dose plus infusion center fees ($200–$500). Over 12 weeks, Tiona’s total cost ($65–$450) is 63–89% lower than IV iron regimens while delivering comparable hematologic outcomes.

Access barriers exist: only 37% of community health centers stock Tiona on-site, requiring mail-order fulfillment (typically 3–5 business days). To mitigate delays, I collaborate with OB-GYN offices to initiate prescriptions at the first prenatal visit for high-risk patients—those with prior IDA, BMI > 30, vegetarian/vegan diets, or short interpregnancy intervals (< 18 months). Early initiation prevents hemoglobin decline during the critical second-trimester expansion phase, when plasma volume increases 40–50% but red blood cell mass rises only 20–30%.

In summary, Tiona represents a meaningful advancement in prenatal iron therapy—not because it replaces foundational nutrition or clinical vigilance, but because it removes a key barrier to adherence. When patients keep taking their iron, hemoglobin rises, fatigue lifts, and birth outcomes improve. That’s not theoretical. It’s measurable, reproducible, and increasingly accessible. As prenatal care evolves toward personalized, tolerance-informed protocols, Tiona offers a data-backed option that honors both physiology and lived experience.